Mark Cuban’s war on America’s $5 trillion healthcare machine: ‘They can’t react as quickly’

Billionaire entrepreneur and investor Mark Cuban thinks the American health care industry is broken, and he is not talking about it.

“Nobody sees the financial aspect of healthcare and says, ‘This should work,’ ‘Cuban says in this week’s episode Equity Podcast “When you go to the doctor and you will get a prescription. You have no idea what you are about to cost you you don’t know if you can afford it.”

The minority owner of the former “Shark Tank” host and Dallas Mavarix Basketball team explains the root of the problem: most drugs are set by the Pharmacy Benefit Manager (PBMS) or third party, which operates prescription drug programs. Cuban said the price of drugs is opaque through design.

This is exactly why he turned on Plus drugs to spend In 2022 – Drawing the screen on the price of drugs, reduce the cost for the average customer and disrupts the traditional pharmacy industry.

“They pay the price in the market; we determine the price on expenses,” he said.

The difference is shocked. For example, a generic chemotherapy can spend thousands of the counter at the drug pharmacy, where it cost plus drugs “can spend $ 21,” said Cuban.

Cuba outlook is different than how the drugs are priced in the United States, as it refers to its name, the cost plus drugs sell the meds directly to the customers at transparent prices – more than 15% markup, plus a $ 5 firm fee, as well as shipping.

“And we are adding the ability to pick it up in a local pharmacy,” added Cuban.

To understand why the Cuban model is disruptive, it helps to know why drugs spend so much in the first place. This industry has protected the practice of additional charging for drugs in the United States-which is one of the only high-income countries whose government does not determine or discuss the price of drugs-by arguing that companies cannot invest billions of dollars needed to bring new drugs to market.

However, critics argued that prices were ready for the maximum profit and not directly bound to research and development expenditure. One Study of 2021 It has been found that income from the top 20 best -selling drugs was enough to return billions of delays from their R&D expenditure.

Cuban is the sky -kissed in the United States: Artificial deficiencies have also mentioned another reason. “Believe it or not, in these days and ages, there are things like pediatric cancer drugs, peatosin, sterile water [and] I can’t even pronounce this long list of drugs, which goes into short supply because manufacturers want to get to their short supply, because they jack the price, “said Cuban.

Although there is limited direct evidence of deliberate gain, it is true that it is true TimePrice UpliftingThe

His answer? Create its own factory. Dallas has a manufacturing plant in Cuba that “all robotics powered”.

“We’ve built this factory where we can turn a new drug into four hours and send it to the hospital,” he also said. “And so we’re starting to attack these deficiencies.”

Patients have a razor-thin margin for drug shipping, but drug production such as cost plus other aspects of drug drugs is more profitable and helps business to profit. Production is also another way to challenge the drug supply chain.

However, the Cuba strategy has just gone out of cheap drug supply – he says he is refusing to play the rules completely. “Everyone was saying … you can’t fight these big companies, insurance carriers, PBMS,” he said. “I like, ‘Okay, I just won’t work with them i

Even the Cuban mentioned that Amazon was in the trap. Tech giants have partnerships with PBMS through Amazon Pharmacy, but it has put the big technical agency a disadvantage because it is still “monitoring PBMS”.

Trying to bring down the lawyer to the founders?

“Don’t rely on them,” he said. “Because if I am 25 years old and start this business I will probably work through the Pharmacy Benefit Managers because this is where this money is.

Cuban said, “When I started, someone told me it: ‘When you ran with elephants there are fast and dead,” said Cuban. “You will become faster, or you will die, and so you have to be thin. You will be able to adapt to you you will be able to wake up and wake up and always find ways to do better, because it’s a matter of the entire inventor’s dilemma. [the incumbents]Isn’t it? They can protect their inheritance business but they can’t move that faster. They can’t respond quickly and so it always gives the founder an edge ””